SG Americas Securities LLC Grows Position in Collegium Pharmaceutical, Inc. $COLL

SG Americas Securities LLC boosted its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 284.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 66,397 shares of the specialty pharmaceutical company’s stock after acquiring an additional 49,123 shares during the period. SG Americas Securities LLC’s holdings in Collegium Pharmaceutical were worth $2,196,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in the business. Group One Trading LLC purchased a new stake in shares of Collegium Pharmaceutical in the 4th quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd increased its holdings in Collegium Pharmaceutical by 205.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock valued at $29,000 after buying an additional 427 shares during the period. Kemnay Advisory Services Inc. bought a new position in Collegium Pharmaceutical in the fourth quarter worth approximately $61,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Collegium Pharmaceutical by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock worth $71,000 after buying an additional 318 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its holdings in Collegium Pharmaceutical by 744.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock worth $73,000 after buying an additional 2,190 shares during the period.

Collegium Pharmaceutical Price Performance

NASDAQ COLL opened at $35.87 on Thursday. The firm’s fifty day simple moving average is $34.20 and its two-hundred day simple moving average is $39.36. The company has a current ratio of 1.71, a quick ratio of 1.62 and a debt-to-equity ratio of 2.47. Collegium Pharmaceutical, Inc. has a 12-month low of $29.19 and a 12-month high of $50.79. The firm has a market capitalization of $1.16 billion, a P/E ratio of 17.58 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.52 by $0.24. The firm had revenue of $193.52 million during the quarter, compared to analyst estimates of $184.47 million. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The business’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.49 EPS. Analysts forecast that Collegium Pharmaceutical, Inc. will post 6.76 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, March 20th. Wall Street Zen upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Needham & Company LLC restated a “buy” rating and set a $56.00 price objective (up from $54.00) on shares of Collegium Pharmaceutical in a research note on Thursday, March 19th. Zacks Research raised Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Monday. Finally, Truist Financial upgraded Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, Collegium Pharmaceutical currently has a consensus rating of “Buy” and an average price target of $57.50.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.